9.2 Acute Anaphylaxis Recognition, Emergency Protocols, and Intramuscular Epinephrine Dosing
Key Takeaways
- Anaphylaxis is an acute, life-threatening systemic hypersensitivity reaction that can be IgE-mediated or non-IgE-mediated and may present with severe airway or cardiovascular findings even without hives.
- Intramuscular (IM) epinephrine 1:1,000 (1 mg/mL) injected into the anterolateral thigh (vastus lateralis) is the absolute first-line drug of choice; it must be administered immediately without delay for secondary medications.
- IM epinephrine uses 0.01 mg/kg of 1 mg/mL solution when weight-based drawing is supported (usual maximum 0.5 mg for larger patients); use the weight-appropriate autoinjector—commonly 0.15 mg for 15 to <30 kg and 0.3 mg at ≥30 kg—according to protocol.
- Epinephrine dosing may be repeated every 5 to 15 minutes if clinical symptoms persist, progress, or fail to resolve; Emergency Medical Services (911) must be activated immediately upon recognizing anaphylaxis or administering the first epinephrine dose.
- Supportive measures such as oxygen, an inhaled bronchodilator for persistent bronchospasm, or an H1 antihistamine for cutaneous symptoms are adjunctive and must never delay or substitute for prompt intramuscular epinephrine administration.
Acute Anaphylaxis Recognition, Emergency Protocols, and Intramuscular Epinephrine Dosing
Core Principle: Anaphylaxis is a medical emergency where seconds count. Intramuscular epinephrine (1:1,000) injected into the anterolateral aspect of the middle third of the vastus lateralis (thigh) is the sole first-line pharmacotherapy that halts and reverses multi-organ collapse. Never delay epinephrine administration to give antihistamines, check insurance, or await physician consultation.
While severe systemic allergic reactions following immunization are exceptionally rare—occurring at an estimated rate of approximately 1 to 5 cases per 1,000,000 vaccine doses—community pharmacies and immunization clinics must operate under constant state of readiness. Every immunizing pharmacy technician and supervising pharmacist must master the multi-system clinical signs of anaphylaxis, understand the precise pharmacological mechanics of epinephrine, and execute emergency rescue protocols flawlessly.
1. Pathophysiology of Vaccine-Induced Anaphylaxis
Vaccine-associated anaphylaxis can be IgE-mediated or arise through other mast-cell activation pathways. Diagnosis is clinical; do not delay treatment while trying to identify the mechanism or excipient.
+-----------------------------------------------------------------------------+
| PATHOPHYSIOLOGY OF TYPE I ANAPHYLAXIS |
| |
| [INITIAL SENSITIZATION PHASE] |
| Antigen exposure -> CD4+ Th2 activation -> Plasma cells produce IgE |
| -> IgE binds with high affinity to Fc-epsilon-RI receptors on mast cells |
| and circulating basophils |
| | |
| v |
| [RE-EXPOSURE / VACCINE INJECTION] |
| Multivalent vaccine antigen cross-links pre-formed IgE on mast cell surface|
| | |
| v |
| [EXPLOSIVE CELLULAR DEGRANULATION] |
| Instantaneous release of pre-formed and newly synthesized mediators: |
| • Histamine (H1, H2 receptor activation) |
| • Tryptase, Chymase, Carboxypeptidase |
| • Leukotrienes (LTC4, LTD4, LTE4 - slow-reacting substance of anaphylaxis)|
| • Prostaglandin D2 (PGD2), Platelet-Activating Factor (PAF) |
| | |
| v |
| [SYSTEMIC MULTI-ORGAN PHYSIOLOGICAL COLLAPSE] |
| • Vascular: Massive systemic capillary vasodilation + plasma leakage |
| -> Up to 35% of intravascular volume extravasates in 10 minutes |
| • Respiratory: Smooth muscle bronchospasm + mucosal laryngeal edema |
| • Cardiac: Coronary vasospasm, profound hypotension, shock |
| • Cutaneous: Dermal edema (urticaria), intense pruritus, angioedema |
| • Gastrointestinal: Intestinal smooth muscle hypermotility & cramping |
+-----------------------------------------------------------------------------+
2. Multi-Organ System Clinical Presentation
Anaphylaxis is defined clinically by acute onset (minutes to hours) involving two or more body organ systems, or sudden cardiovascular collapse following exposure to a known or suspected allergen.
| Body Organ System | Characteristic Signs & Symptoms | Clinical Significance & Risk |
|---|---|---|
| Cutaneous & Mucosal<br>(Present in >90% of cases) | • Generalized Urticaria: Widespread raised, intensely pruritic, erythematous wheals (hives)<br>• Angioedema: Deep dermal/submucosal swelling of lips, tongue, uvula, soft palate, eyelids, or hands<br>• Pruritus & Flushing: Intense generalized itching (especially palms, soles, groin), warm erythematous flush | Most common presenting manifestation; serves as early visual confirmation of systemic mast cell degranulation. |
| Respiratory<br>(Present in ~70% of cases) | • Upper Airway (Laryngeal Edema): Inspiratory stridor, hoarseness, dysphonia, feeling of throat closing or lump in throat<br>• Lower Airway (Bronchospasm): Expiratory wheezing, tachypnea, severe dyspnea, intercostal retractions, cyanosis, persistent dry barking cough | Primary cause of immediate asphyxiation and death; requires rapid reversal before complete glottic closure occurs. |
| Cardiovascular<br>(Present in ~45% of cases) | • Systemic Vasodilation: Profound hypotension (systolic BP <90 mmHg or >30% drop from baseline)<br>• Tachycardia: Rapid, weak, thready pulse (compensatory reflex)<br>• Cardiovascular Collapse: Dizziness, diaphoresis, syncope, pallor/cyanosis, cardiac arrest | Third-spacing of fluid leads to distributive shock and "empty ventricle syndrome" (pulseless electrical activity). |
| Gastrointestinal<br>(Present in ~30–45% of cases) | • Hypermotility & Spasm: Severe, crampy abdominal pain<br>• Upper GI: Repetitive nausea, projectile vomiting<br>• Lower GI: Profuse watery diarrhea, fecal urgency | Indicates extensive systemic mediator dissemination across mucosal surfaces. |
| Neurological & Psychological | • Sense of "Impending Doom": Severe anxiety, agitation, terror<br>• Hypoxic Encephalopathy: Confusion, lethargy, loss of consciousness | Triggered by sudden cerebral hypoperfusion and endogenous catecholamine/inflammatory surges. |
[!WARNING] Atypical Anaphylaxis Without Cutaneous Signs: In approximately 10% to 15% of life-threatening anaphylactic episodes, cutaneous signs (hives or angioedema) may be completely absent or delayed until after cardiovascular collapse occurs. Rapid onset of isolated respiratory distress (stridor/wheezing) or sudden profound hypotension following vaccination must be treated immediately as anaphylaxis.
3. Epinephrine: The First-Line Life-Saving Drug
Epinephrine (adrenaline) is the absolute first-line drug for the treatment of acute anaphylaxis. There are NO absolute contraindications to epinephrine administration in a life-threatening anaphylactic emergency.
Pharmacology and Receptor Mechanisms
Epinephrine is a non-selective, potent agonist at alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors:
- Alpha-1 Adrenergic Agonism: Produces potent peripheral vasoconstriction, increasing systemic vascular resistance (SVR), elevating blood pressure, and reversing capillary leak and mucosal edema (reducing laryngeal swelling).
- Beta-1 Adrenergic Agonism: Increases myocardial contractility (positive inotropy) and heart rate (positive chronotropy), improving cardiac output and coronary perfusion.
- Beta-2 Adrenergic Agonism: Induces powerful bronchial smooth muscle relaxation (relieving bronchospasm and wheezing) and inhibits further mast cell and basophil degranulation by increasing intracellular cyclic adenosine monophosphate (cAMP).
+-----------------------------------------------------------------------------+
| PHARMACOLOGICAL ACTIONS OF RESCUE EPINEPHRINE |
| |
| +------------------- EPINEPHRINE -------------------+ |
| | | |
| v v |
| [ALPHA-1 RECEPTORS] [BETA-2 RECEPTORS] |
| • Peripheral Vasoconstriction • Bronchodilation |
| • Reverses Capillary Permeability (Opens Airway) |
| • Elevates Systemic BP • Halts Degranulation|
| • Decreases Glottic/Laryngeal Edema (Blocks Histamine)|
| |
| v |
| [BETA-1 RECEPTORS] |
| • Increases Heart Rate |
| • Increases Cardiac Contractility |
| • Restores Cardiac Output |
+-----------------------------------------------------------------------------+
Why Intramuscular (IM) Vastus Lateralis is Mandatory
- Route: Epinephrine must be administered INTRAMUSCULARLY (IM).
- Anatomical Site: The anterolateral aspect of the middle third of the thigh (vastus lateralis) is the mandatory anatomical site.
- Pharmacokinetic Rationale: Pharmacokinetic trials prove that IM injection into the vastus lateralis achieves peak plasma epinephrine concentrations ($C_{max}$) within 8 to 10 minutes. In contrast, subcutaneous (SC) administration requires 34 to 45 minutes to reach peak levels due to local alpha-1 mediated vasoconstriction, and IM deltoid injection yields substantially lower and slower peak plasma levels.
- Safety Warning: NEVER administer epinephrine 1:1,000 intravenously (IV) as a bolus, as IV bolus administration of this concentrated formulation can trigger lethal ventricular arrhythmias, severe hypertension, or intracranial hemorrhage.
4. Master Emergency Dosage and Administration Table
Pharmacy personnel must know the exact weight-based dosing, volume concentrations, and autoinjector specifications for epinephrine.
| Patient Category | Weight (kg / lbs) | Epinephrine 1:1,000 (1 mg/mL) Aqueous Solution Dosing | Autoinjector Formulation | Needle Length & Gauge |
|---|---|---|---|---|
| Adults & Adolescents | >= 30 kg<br>(>= 66 lbs) | 0.3 mg to 0.5 mg IM<br>(0.3 mL to 0.5 mL of 1:1,000 solution) | 0.3 mg Autoinjector<br>(e.g., EpiPen, Auvi-Q 0.3 mg) | 1 inch to 1.5 inch, 22–25 gauge needle (vastus lateralis) |
| Pediatrics | 15 kg to <30 kg<br>(33 lbs to <66 lbs) | 0.01 mg/kg IM of 1 mg/mL solution when weight-based drawing is supported (maximum 0.3 mg in this band) | 0.15 mg Autoinjector<br>(e.g., EpiPen Jr, Auvi-Q 0.15 mg) | Follow device/protocol; anterolateral thigh |
| Infants & Small Toddlers | < 15 kg<br>(< 33 lbs) | 0.01 mg/kg IM<br>(0.01 mL/kg of 1:1,000 solution; max initial dose: 0.15 mg) | 0.1 mg Auvi-Q (for 7.5–15 kg) or drawn manually with 1 mL syringe | 7/8 inch to 1 inch, 22–25 gauge needle (vastus lateralis) |
Repeat Dosing Guidelines
- Frequency: Epinephrine may be repeated every 5 to 15 minutes if the patient's symptoms fail to improve, if respiratory distress worsens, or if severe hypotension persists.
- Clinical Reality: Approximately 10% to 20% of anaphylactic episodes require more than one dose of epinephrine to achieve clinical stabilization. The pharmacy emergency kit must always contain multiple epinephrine doses.
5. Seven-Step Anaphylaxis Emergency Action Protocol
+-----------------------------------------------------------------------------+
| SEVEN-STEP ANAPHYLAXIS ACTION PROTOCOL |
| |
| [STEP 1: RAPID RECOGNITION & ABC TRIAGE] |
| - Assess: Airway (stridor/swelling), Breathing (wheezing), Circulation (BP)|
| - Shout for pharmacy team support; alert supervising pharmacist |
| | |
| v |
| [STEP 2: ADMINISTER FIRST-LINE IM EPINEPHRINE IMMEDIATELY] |
| - Adult: 0.3-0.5 mg IM in vastus lateralis (anterolateral thigh) |
| - Child: 0.01 mg/kg IM when weight-based dosing is supported; use the weight-appropriate autoinjector otherwise |
| - DO NOT DELAY for vitals, antihistamines, or ice packs |
| | |
| v |
| [STEP 3: ACTIVATE EMERGENCY MEDICAL SERVICES (CALL 911)] |
| - Direct technician or staff: "Call 911 immediately; state anaphylaxis" |
| - Request ALS (Advanced Life Support) response unit |
| | |
| v |
| [STEP 4: PROPER PATIENT POSITIONING] |
| - Place patient SUPINE with legs ELEVATED 12 inches |
| - If vomiting/airway secretions: LEFT LATERAL RECOVERY POSITION |
| - If severe dyspnea: Allow seated/leaning forward position |
| - STRICTLY FORBID SUDDEN STANDING OR WALKING ("Empty Ventricle Syndrome") |
| | |
| v |
| [STEP 5: AIRWAY, OXYGEN, & VITAL SIGNS MONITORING] |
| - Administer high-flow supplemental oxygen (10-15 L/min via non-rebreather)|
| - Monitor BP, heart rate, respiratory rate, and SpO2 every 2-5 minutes |
| - Be prepared to initiate CPR / chest compressions if pulse is lost |
| | |
| v |
| [STEP 6: REPEAT EPINEPHRINE IF SYMPTOMS PERSIST] |
| - If no improvement within 5 to 15 minutes, inject second IM dose |
| | |
| v |
| [STEP 7: SECONDARY ADJUNCTIVE THERAPIES (ONLY AFTER EPINEPHRINE)] |
| - Diphenhydramine 25-50 mg IM/oral (relieves itching/urticaria) |
| - Antihistamine for hives/itching only, per standing order |
| - Inhaled Albuterol (2.5 mg nebulized or 4-8 puffs MDI) for bronchospasm |
+-----------------------------------------------------------------------------+
Critical Patient Positioning Rules: Preventing Empty Ventricle Syndrome
- The Empty Ventricle Phenomenon: In anaphylactic shock, massive capillary vasodilation and plasma extravasation cause severe central hypovolemia. If an anaphylactic patient suddenly sits upright or stands, gravity immediately causes the remaining venous blood to pool in the lower extremities, completely depriving the right ventricle of preload. This triggers instantaneous cardiovascular collapse, pulseless electrical activity (PEA), and death within seconds.
- Positioning Mandates:
- Standard: Supine with lower extremities elevated 12 inches.
- Airway Compromise / Vomiting: Left lateral decubitus position (recovery position) to prevent asphyxiation from aspiration.
- Severe Respiratory Distress: Semi-Fowler position (seated slightly elevated), but strictly avoid sudden standing or ambulation.
6. Secondary Adjunctive Therapies (Strictly Secondary)
Secondary medications do NOT treat airway edema, reverse bronchospasm, or restore blood pressure. They must never be given before or in place of epinephrine.
- H1-Antihistamines (e.g., Diphenhydramine 25 to 50 mg IM or Oral):
- Mechanism: Competitive H1-receptor antagonist.
- Indication: Relieves secondary cutaneous symptoms (pruritus, urticaria, facial flushing).
- Limitations: Takes 30 to 60 minutes for oral onset; does not reverse laryngeal edema or shock.
- H2-Antihistamines (e.g., oral or IV famotidine in an advanced-care protocol):
- Mechanism: Competitive H2-receptor antagonist.
- Indication: Provides synergistic cutaneous relief when combined with H1 antagonists.
- Inhaled Short-Acting Beta-2 Agonists (e.g., Albuterol 2.5 mg nebulized or 4–8 puffs MDI):
- Mechanism: Direct bronchial smooth muscle relaxation.
- Indication: Treats residual bronchospasm and wheezing refractory to initial epinephrine.
- Systemic Corticosteroids (e.g., Methylprednisolone or Prednisone):
- Mechanism: Anti-inflammatory gene transcription modulation.
- Indication: Historically used to reduce the risk of biphasic (recurrent) anaphylaxis; however, clinical onset requires 4 to 6 hours.
7. Pharmacy Emergency Kit Mandatory Standards
Every vaccination site must be prepared to recognize anaphylaxis, call EMS, and give epinephrine immediately. The exact emergency-kit inventory is set by applicable law, standing orders, and site protocol; CDC identifies epinephrine and basic assessment/resuscitation supplies as core readiness items.
+-----------------------------------------------------------------------------+
| SITE-SPECIFIC PHARMACY EMERGENCY KIT INVENTORY |
| |
| 1. EPINEPHRINE RESCUE DRUGS |
| • Minimum 2 to 3 Adult Epinephrine Autoinjectors (0.3 mg) OR |
| Epinephrine 1:1,000 (1 mg/mL) ampules/vials (minimum 3 mL) |
| • Minimum 2 Pediatric Epinephrine Autoinjectors (0.15 mg) OR |
| Auvi-Q / Pediatric dosing equivalents |
| |
| 2. ADMINISTRATION SUPPLIES |
| • 1 mL Tuberculin syringes with attached 22-25G needles (1" and 1.5") |
| • Alcohol prep pads (70% isopropyl alcohol) |
| • Blunt fill / filter needles (for glass ampule preparation) |
| |
| 3. AIRWAY & RESUSCITATION GEAR |
| • Adult and pediatric pocket masks with one-way valves (CPR masks) |
| • Bag-valve-mask (BVM) resuscitator (if required by state protocol) |
| |
| 4. DIAGNOSTIC & MONITORING EQUIPMENT |
| • Sphygmomanometer (blood pressure cuff: adult, large adult, pediatric)|
| • Stethoscope |
| • Pulse oximeter with real-time waveform display |
| |
| 5. ADJUNCTIVE MEDICATIONS & PROTOCOL DOCUMENTATION |
| • Diphenhydramine (oral 25 mg tablets/liquid, injectable 50 mg/mL) |
| • Laminated copy of Clinic Anaphylaxis Emergency Standing Order |
| • Emergency contact placard (911, Poison Control, Local Hospital ED) |
+-----------------------------------------------------------------------------+
[!IMPORTANT] Technician Maintenance Duties: Pharmacy technicians are responsible for the monthly physical audit of the emergency kit. This includes logging inspection dates, verifying that epinephrine solutions are crystal clear and colorless (discarding any discolored or precipitated vials), verifying that needle/syringe packaging is intact, and replacing any medications prior to the last day of the expiration month.
A 42-year-old female (weight: 68 kg) receives an intramuscular recombinant zoster vaccine. Eight minutes post-injection, she reports severe throat tightness, dyspnea, and intense itching. The pharmacy team observes perioral angioedema, widespread erythematous hives across her neck and chest, audible inspiratory stridor, and a blood pressure of 82/50 mmHg. What is the mandatory first-line intervention?
An 8-year-old child weighing 24 kg develops severe anaphylaxis after influenza vaccination. The clinic uses premeasured autoinjectors. Which available device and route are appropriate under current CDC guidance?
A patient exhibiting signs of severe anaphylactic shock is lying supine on the pharmacy floor after receiving an intramuscular epinephrine injection. The patient states they feel slightly better and attempts to stand up to walk to the restroom. Why must the pharmacy team strictly instruct the patient to remain supine with legs elevated?